Title : Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Pub. Date : 2010 Oct

PMID : 20680681






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We investigated to compare the effects of the addition of tamoxifen to epirubicin versus epirubicin alone on VEGF and VEGFR2 expression in breast cancer patients. Epirubicin vascular endothelial growth factor A Homo sapiens
2 The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin plus tamoxifen as primary systemic treatment. Epirubicin vascular endothelial growth factor A Homo sapiens
3 The expression of VEGF and VEGFR2 was assessed on tissue microarray by immunohistochemistry at baseline conditions and after treatments in the case of 191 patients with T2-4 N0-1 breast cancer enrolled in a randomized trial comparing four cycles of single agent epirubicin versus epirubicin plus tamoxifen as primary systemic treatment. Epirubicin vascular endothelial growth factor A Homo sapiens
4 Epirubicin alone failed to induce changes in VEGF expression (P = 0.54), while the addition of tamoxifen to epirubicin resulted in a significant reduction in VEGF expression (P < 0.001). Epirubicin vascular endothelial growth factor A Homo sapiens
5 As a consequence, baseline VEGF had a negative prognostic role in patients who received epirubicin alone but not in patients receiving epirubicin plus tamoxifen (interaction test P < 0.05). Epirubicin vascular endothelial growth factor A Homo sapiens